Literature DB >> 27590896

Cannabis sativa allergy: looking through the fog.

I I Decuyper1,2, A L Van Gasse1,2, N Cop1, V Sabato1, M A Faber1, C Mertens1, C H Bridts1, M M Hagendorens1,2, L De Clerck1, H P Rihs3, D G Ebo1.   

Abstract

IgE-mediated Cannabis (C. sativa, marihuana) allergy seems to be on the rise. Both active and passive exposure to cannabis allergens may trigger a C. sativa sensitization and/or allergy. The clinical presentation of a C. sativa allergy varies from mild to life-threatening reactions and often seems to depend on the route of exposure. In addition, sensitization to cannabis allergens can result in various cross-allergies, mostly for plant foods. This clinical entity, designated as the 'cannabis-fruit/vegetable syndrome', might also imply cross-reactivity with tobacco, natural latex and plant-food-derived alcoholic beverages. Hitherto, these cross-allergies are predominantly reported in Europe and appear mainly to rely upon cross-reactivity between nonspecific lipid transfer proteins or thaumatin-like proteins present in C. sativa and their homologues, ubiquitously distributed throughout plant kingdom. At present, diagnosis of cannabis-related allergies predominantly rests upon a thorough history completed with skin testing using native extracts from crushed buds and leaves. However, quantification of specific IgE antibodies and basophil activation tests can also be helpful to establish correct diagnosis. In the absence of a cure, treatment comprises absolute avoidance measures. Whether avoidance of further use will halt the extension of related cross-allergies remains uncertain.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990Cannabis sativazzm321990; IgE; basophil activation; cross-reactivity; diagnosis

Mesh:

Substances:

Year:  2016        PMID: 27590896     DOI: 10.1111/all.13043

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  6 in total

Review 1.  Occupational Allergies to Cannabis.

Authors:  Ine I Decuyper; Brett J Green; Gordon L Sussman; Didier G Ebo; William S Silvers; Karin Pacheco; Bradley S King; John R Cohn; Robert S Zeiger; Joanna S Zeiger; David R Naimi; Donald H Beezhold; Ajay P Nayak
Journal:  J Allergy Clin Immunol Pract       Date:  2020 Nov - Dec

2.  Review of NIOSH Cannabis-Related Health Hazard Evaluations and Research.

Authors:  James R Couch; George Reed Grimes; Brett J Green; Douglas M Wiegand; Bradley King; Mark M Methner
Journal:  Ann Work Expo Health       Date:  2020-08-06       Impact factor: 2.179

3.  Marijuana and stoned fruit.

Authors:  Prerana Bhatia; Meng Chen; Sandra Christiansen
Journal:  Ann Allergy Asthma Immunol       Date:  2018-02-02       Impact factor: 6.347

4.  Allergic and Respiratory Symptoms in Employees of Indoor Cannabis Grow Facilities.

Authors:  Coralynn Sack; Niloufar Ghodsian; Karen Jansen; Brynne Silvey; Christopher D Simpson
Journal:  Ann Work Expo Health       Date:  2020-08-06       Impact factor: 2.779

Review 5.  Cannabis, the Endocannabinoid System and Immunity-the Journey from the Bedside to the Bench and Back.

Authors:  Osnat Almogi-Hazan; Reuven Or
Journal:  Int J Mol Sci       Date:  2020-06-23       Impact factor: 5.923

Review 6.  Opportunities for cannabis in supportive care in cancer.

Authors:  Amber S Kleckner; Ian R Kleckner; Charles S Kamen; Mohamedtaki A Tejani; Michelle C Janelsins; Gary R Morrow; Luke J Peppone
Journal:  Ther Adv Med Oncol       Date:  2019-08-01       Impact factor: 8.168

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.